Overview

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity will be evaluated.

Phase:

Phase 1

Details

Lead Sponsor:

AI Therapeutics, Inc.
Lam Therapeutics Inc.

Treatments:

Atezolizumab
Rituximab